Your browser doesn't support javascript.
loading
Early psoriatic arthritis: clinical and therapeutic challenges.
Caso, Francesco; Costa, Luisa; Megna, Matteo; Cascone, Mario; Maione, Francesco; Giacomelli, Roberto; Scarpa, Raffaele; Ruscitti, Piero.
Affiliation
  • Caso F; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  • Costa L; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  • Megna M; Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy.
  • Cascone M; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  • Maione F; ImmunoPharmaLab, Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  • Giacomelli R; Research and Clinical Unit of immunorheumatology, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy.
  • Scarpa R; Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
  • Ruscitti P; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Article in En | MEDLINE | ID: mdl-39041193
ABSTRACT

INTRODUCTION:

Psoriatic arthritis (PsA) is a chronic immunoinflammatory disease of the enthesis and adjacent synovium, skin, and nail, which early diagnosis may be crucial for starting a prompt therapeutic intervention. Theoretically, early treatment offers the advantage of acting on the reduction of the articular damage progression since initial phases of the disease. AREAS COVERED This review explores the challenges of clinical-diagnostic aspects and the underlying pathophysiology of early PsA phases, as well as the evidence evaluating the impact of early intervention on disease outcomes. EXPERT OPINION Main instruments for early PsA diagnosis include recognizing synovial-entheseal inflammatory signs at onset, improving screening PsA high-risk subjects, and increasing disease knowledge of physicians and patients with psoriasis or familial history.PsA continues to significantly impact on the Quality of Life of patients affected by the disease, making necessary to deeply study clinical manifestations, risk factors and underlying immunoinflammatory mechanisms, as well as to identify biomarkers for early identification. Additionally, it remains a need to increase more evidence on understanding how early treatment of PsA and of psoriasis might influence the course of the disease.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Expert Opin Investig Drugs Journal subject: TERAPIA POR MEDICAMENTOS Year: 2024 Document type: Article Affiliation country: Italy

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Expert Opin Investig Drugs Journal subject: TERAPIA POR MEDICAMENTOS Year: 2024 Document type: Article Affiliation country: Italy